• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

Use Able AI chat for product recommendations
  • Various lysates were subjected to SDS PAGE followed by western blot with 81670-1-RR (mTOR antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

    Various lysates were subjected to SDS PAGE followed by western blot with 81670-1-RR (mTOR antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

  • WB result of mTOR antibody (81670-1-RR; 1:3000; incubated at room temperature for 1.5 hours) with sh-Control and sh-mTOR transfected HeLa cells.

    WB result of mTOR antibody (81670-1-RR; 1:3000; incubated at room temperature for 1.5 hours) with sh-Control and sh-mTOR transfected HeLa cells.

  • Non-treated and Calyculin A treated HEK-293 cells were subjected to SDS PAGE followed by western blot with 80596-1-RR (Phospho-mTOR (Ser2448) antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with RICTOR antibody (66867-2-Ig) subsequently.

    Non-treated and Calyculin A treated HEK-293 cells were subjected to SDS PAGE followed by western blot with 80596-1-RR (Phospho-mTOR (Ser2448) antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with RICTOR antibody (66867-2-Ig) subsequently.

  • Non-treated and Calyculin A treated HeLa cells were subjected to SDS PAGE followed by western blot with 80596-1-RR (Phospho-mTOR (Ser2448) antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with RICTOR antibody (66867-2-Ig) subsequently.

    Non-treated and Calyculin A treated HeLa cells were subjected to SDS PAGE followed by western blot with 80596-1-RR (Phospho-mTOR (Ser2448) antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with RICTOR antibody (66867-2-Ig) subsequently.

  • Non-treated and IGF-1 treated MCF-7 cells were subjected to SDS PAGE followed by western blot with 82373-1-RR (Phospho-p70(S6K) (Thr389) antibody) at dilution of 1:40000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with beta actin antibody (66009-1-Ig) as loading control.

    Non-treated and IGF-1 treated MCF-7 cells were subjected to SDS PAGE followed by western blot with 82373-1-RR (Phospho-p70(S6K) (Thr389) antibody) at dilution of 1:40000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with beta actin antibody (66009-1-Ig) as loading control.

  • Non-treated HEK-293T cells, phosphatase inhibitor treated HEK-293T cells and λ phosphatase treated HEK-293T cells were subjected to SDS PAGE followed by western blot with 81812-4-RR (Phospho-4EBP1 (Thr37) antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Alpha Tubulin (66031-1-Ig) antibody as a loading control.

    Non-treated HEK-293T cells, phosphatase inhibitor treated HEK-293T cells and λ phosphatase treated HEK-293T cells were subjected to SDS PAGE followed by western blot with 81812-4-RR (Phospho-4EBP1 (Thr37) antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Alpha Tubulin (66031-1-Ig) antibody as a loading control.

  • Non-treated and PDGF treated HEK-293 cells were subjected to SDS PAGE followed by western blot with 80130-2-RR (RPS6-phospho-S235/236 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Beta Actin (66009-1-Ig) antibody as a loading control.

    Non-treated and PDGF treated HEK-293 cells were subjected to SDS PAGE followed by western blot with 80130-2-RR (RPS6-phospho-S235/236 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours. The membrane was stripped and re-blotted with Beta Actin (66009-1-Ig) antibody as a loading control.

  • IP result of anti-mTOR (IP:81670-1-RR, 4ug; Detection:81670-1-RR 1:1000) with HeLa cells lysate 1760 ug.

    IP result of anti-mTOR (IP:81670-1-RR, 4ug; Detection:81670-1-RR 1:1000) with HeLa cells lysate 1760 ug.

  • Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 81670-1-RR (mTOR antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

    Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 81670-1-RR (mTOR antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

  • Immunofluorescent analysis of (-20°C Methanol) fixed HepG2 cells using mTOR antibody (81670-1-RR, Clone: 6H23 ) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

    Immunofluorescent analysis of (-20°C Methanol) fixed HepG2 cells using mTOR antibody (81670-1-RR, Clone: 6H23 ) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

  • Immunofluorescent analysis of (4% PFA) fixed PMA treated HEK-293 cells using Phospho-mTOR (Ser2448) antibody (80596-1-RR, Clone: 3L18 ) at dilution of 1:1000 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-phalloidin (red).

    Immunofluorescent analysis of (4% PFA) fixed PMA treated HEK-293 cells using Phospho-mTOR (Ser2448) antibody (80596-1-RR, Clone: 3L18 ) at dilution of 1:1000 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-phalloidin (red).

  • 1X10^6 HeLa cells were intracellularly stained with 0.4 ug Anti-Human mTOR (81670-1-RR, Clone:6H23) and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Isotype Control. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer.

    1X10^6 HeLa cells were intracellularly stained with 0.4 ug Anti-Human mTOR (81670-1-RR, Clone:6H23) and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Isotype Control. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer.

mTOR Substrates Antibody Kit

Cat No. PK30025

Host

Rabbit

Reactivity

Target Dependent

Applications

Target Dependent

Conjugate

Unconjugated

Size: 

-/ -

ご購入について

国内販売は「コスモ・バイオ株式会社」を通じて行っております。お見積り・ご注文はお近くの販売代理店へご連絡ください。

国内在庫・納期について

約2万点のプロテインテック製品をコスモバイオ社物流センター（国内）に在庫しています。国内在庫の有無はコスモバイオ社ホームページの「品番検索」でカタログ番号を検索して確認できます。

保証・サポートについて

テクニカルサポートまたはご購入後1年間の交換／補填対応を承ります。詳細はこちらをご覧ください。

Product Information

The mTOR Substrates Antibody Kit provides a cost-effective tool for studying mTOR activation as well as key proteins that are phosphorylated downstream. Perfect for signal transduction researchers starting a new project, screening multiple prospective targets, or those who simply require less volume.  

The mTOR Substrates Antibody Kit contains antibodies against 5 key phospho-protein targets of the mTOR pathway.

Antigen Catalog No. Host, clonality Tested Reactivity Applications Volume

mTOR

81670-1-RR             Rabbit Monoclonal             H, M, R WB, IP, IHC, IF/ICC, FC (Intra) 20 uL

Phospho-mTOR

(Ser2448)

80596-1-RR             Rabbit Monoclonal H, R             WB, IF/ICC 20 uL

Phospho-p70(S6K)

(Thr389)

82373-1-RR             Rabbit Monoclonal H WB 20 uL

Phospho-4EBP1

(Thr37)

81812-4-RR             Rabbit Monoclonal H WB 20 uL

Phospho-RPS6

(Ser235/236)

80130-2-RR             Rabbit Monoclonal             H             WB 20 uL            


Storage

Store at -20°C. Stable for one year from the date of receipt. 

Background Information

The mammalian target of rapamycin (mTOR) forms the center of a powerful signaling pathway that regulates cell metabolism, proliferation, and survival. Its activation is contingent upon phosphorylation at the Ser2448 residue, which is typically mediated upstream by AKT. The activated mTOR can then phosphorylate multiple substrates downstream to control the various effector functions of the mTOR pathway. Phosphorylation of p70(S6K) at the Thr389 residue results in its full activation and promotion of cell proliferation and mRNA translation via subsequent phosphorylation of RPS6 at the Ser 235 and 236 residues. mTOR can also promote translation through phosphorylation of 4EBP1 at the Thr 37 and 46 residues. These phosphorylation events reduce the ability of 4EBP1 to bind to eIF4E, which in turn reduces the inhibition of cap-dependent translation.

Standard Protocols

Click   here  to view our standard protocols for various applications including WB, IP, IHC, IF, FC, and ELISA.

Cited in Article as

pk30025, mTOR Substrates Antibody Kit, Proteintech, IL, USA

{{ptg:customerreview}}
||
New chat Able
正在加载，请稍候...